Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. / Larsen, Philip J; Holst, Jens Juul.

I: Regulatory Peptides, Bind 128, Nr. 2, 2005, s. 97-107.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Larsen, PJ & Holst, JJ 2005, 'Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter.', Regulatory Peptides, bind 128, nr. 2, s. 97-107. https://doi.org/10.1016/j.regpep.2004.08.026

APA

Larsen, P. J., & Holst, J. J. (2005). Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regulatory Peptides, 128(2), 97-107. https://doi.org/10.1016/j.regpep.2004.08.026

Vancouver

Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regulatory Peptides. 2005;128(2):97-107. https://doi.org/10.1016/j.regpep.2004.08.026

Author

Larsen, Philip J ; Holst, Jens Juul. / Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. I: Regulatory Peptides. 2005 ; Bind 128, Nr. 2. s. 97-107.

Bibtex

@article{52b09320ab5011ddb5e9000ea68e967b,
title = "Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter.",
abstract = "The interest in glucagon-like petide-1 (GLP-1) and other pre-proglucagon derived peptides has risen almost exponentially since seminal papers in the early 1990s proposed to use GLP-1 agonists as therapeutic agents for treatment of type 2 diabetes. A wealth of interesting studies covering both normal and pathophysiological role of GLP-1 have been published over the last two decades and our understanding of GLP-1 action has widened considerably. In the present review, we have tried to cover our current understanding of GLP-1 actions both as a peripheral hormone and as a central neurotransmitter. From an initial focus on glycaemic control, GLP-1 research has been diverted to study its role in energy homeostasis, neurodegeneration, cognitive functions, anxiety and many more functions. With the upcoming introduction of GLP-1 agonists on the pharmaceutical venue, we have witnessed an outstanding example of how initial ideas from basic science laboratories have paved their way to become a novel therapeutic strategy to fight diabetes.",
author = "Larsen, {Philip J} and Holst, {Jens Juul}",
note = "Keywords: Diabetes Mellitus, Type 2; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Neurotransmitter Agents; Peptide Fragments; Proglucagon; Protein Precursors",
year = "2005",
doi = "10.1016/j.regpep.2004.08.026",
language = "English",
volume = "128",
pages = "97--107",
journal = "Regulatory Peptides",
issn = "0167-0115",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter.

AU - Larsen, Philip J

AU - Holst, Jens Juul

N1 - Keywords: Diabetes Mellitus, Type 2; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Neurotransmitter Agents; Peptide Fragments; Proglucagon; Protein Precursors

PY - 2005

Y1 - 2005

N2 - The interest in glucagon-like petide-1 (GLP-1) and other pre-proglucagon derived peptides has risen almost exponentially since seminal papers in the early 1990s proposed to use GLP-1 agonists as therapeutic agents for treatment of type 2 diabetes. A wealth of interesting studies covering both normal and pathophysiological role of GLP-1 have been published over the last two decades and our understanding of GLP-1 action has widened considerably. In the present review, we have tried to cover our current understanding of GLP-1 actions both as a peripheral hormone and as a central neurotransmitter. From an initial focus on glycaemic control, GLP-1 research has been diverted to study its role in energy homeostasis, neurodegeneration, cognitive functions, anxiety and many more functions. With the upcoming introduction of GLP-1 agonists on the pharmaceutical venue, we have witnessed an outstanding example of how initial ideas from basic science laboratories have paved their way to become a novel therapeutic strategy to fight diabetes.

AB - The interest in glucagon-like petide-1 (GLP-1) and other pre-proglucagon derived peptides has risen almost exponentially since seminal papers in the early 1990s proposed to use GLP-1 agonists as therapeutic agents for treatment of type 2 diabetes. A wealth of interesting studies covering both normal and pathophysiological role of GLP-1 have been published over the last two decades and our understanding of GLP-1 action has widened considerably. In the present review, we have tried to cover our current understanding of GLP-1 actions both as a peripheral hormone and as a central neurotransmitter. From an initial focus on glycaemic control, GLP-1 research has been diverted to study its role in energy homeostasis, neurodegeneration, cognitive functions, anxiety and many more functions. With the upcoming introduction of GLP-1 agonists on the pharmaceutical venue, we have witnessed an outstanding example of how initial ideas from basic science laboratories have paved their way to become a novel therapeutic strategy to fight diabetes.

U2 - 10.1016/j.regpep.2004.08.026

DO - 10.1016/j.regpep.2004.08.026

M3 - Journal article

C2 - 15780429

VL - 128

SP - 97

EP - 107

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

IS - 2

ER -

ID: 8418083